



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Linzagolix

Item No. 39654

CAS Registry No.: 935283-04-8

Formal Name: 3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-1,2,3,4-tetrahydro-2,4-dioxo-thieno[3,4-d]pyrimidine-5-carboxylic acid

Synonyms: KLH-2109, OBE-2109

MF: $C_{22}H_{15}F_3N_2O_7S$


FW: 508.4

Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Linzagolix is supplied as a solid. A stock solution may be made by dissolving the linzagolix in the solvent of choice, which should be purged with an inert gas. Linzagolix is soluble in organic solvents such as acetonitrile and DMSO.

Description

Linzagolix is a nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist ($IC_{50} = 36.7$ nM for the human receptor).¹ Unlike the peptide GnRH receptor antagonist cetrorelix (Item No. 23910), linzagolix (10 μM) does not induce histamine release in isolated rat peritoneal mast cells.² Linzagolix (25 and 50 mg/kg) suppresses the menstrual cycle in normal cynomolgus monkeys.¹ It decreases serum luteinizing hormone (LH) levels in ovariectomized cynomolgus monkeys when administered at doses ranging from 1 to 100 mg/kg. Linzagolix (50-200 mg/kg, p.o.) decreases cyst volume in a rat model of endometriosis induced by autotransplantation of endometrial tissue into the renal subcapsular space.² Formulations containing linzagolix have been used in the treatment of uterine fibroids.

References

1. Tezuka, M., Tamai, Y., Kuramochi, Y., *et al.* Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors. *Clin. Exp. Pharmacol. Physiol.* **49**(10), 1082-1093 (2022).
2. Tezuka, M., Tsuchioka, K., Kobayashi, K., *et al.* Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats. *Clin. Exp. Pharmacol. Physiol.* **50**(7), 610-617 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/08/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM